In March 2008, we entered into an Asset Purchase and License Agreement with Emergent BioSolutions for the sale of our anthrax antibodies and license to use our proprietary Xenerex Technology platform, which was used to generate fully human antibodies to target antigens. Under the terms of the agreement, we completed the remaining work under our NIH/NIAID grant and transferred all materials to Emergent. Under the terms of the agreement, we are eligible to receive milestone payments and royalties on any product sales generated from this program. In connection with the sale of the anthrax antibody program, we also ceased all ongoing research and development work related to other infectious disease on June 30, 2008.